Results 31 to 40 of about 2,193 (158)

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice

International Journal of Toxicology, 2022
Pretomanid is a nitroimidazooxazine antimycobacterial drug that was approved as part of a three-drug oral regimen, consisting of bedaquiline, pretomanid, and linezolid, for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis or with complicated forms of multidrug-resistant tuberculosis by the food and drug administration
Jeffrey L. Ambroso, John Dillberger, Rebecca Bruning-Barry, Tian Yang   +3 more
openaire   +2 more sources

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project [PDF]

Open Forum Infectious Diseases, 2021
Abstract Background In August 2019 the U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
Goswami, Neela, Peddareddy, Lakshmi Praveena, Jereb, John, Semidey, Angel Colon, Darnall, Elaine, Macias, Patricia, Jasuja, Supriya, Landers, Karen, Dasgupta, Shom, Oxtoby, Margaret, Spitters, Christopher, Dov, Lana, Narita, Masa, DaSilva, Malini, Cropper, Tracina, Gullickson, Cricket, Ashkin, David, Haley, Connie   +17 more
openaire   +1 more source

A Practical and Economical Route to (S)-Glycidyl Pivalate

SynOpen, 2022
An efficient method to prepare enantiopure (S)-glycidyl pivalate from (R)-epichlorohydrin and pivalic acid is reported. This work provides an alternative to the synthesis of this important building block from readily available and inexpensive materials.
Jeffrey M. Noble, Le Chang, Dan Chen, Binglin Wang, Raymond N. Dominey, Daniel W. Cook, Justina M. Burns, Rodger W. Stringham, Flavio S. P. Cardoso, David R. Snead   +9 more
doaj   +1 more source

Parameters of Complete Blood Count and Blood Chemistry during Treatment of Patients with MDR/XDR Pulmonary Tuberculosis with a Short-Course Regimen Containing Bedaquiline, Pretomanid, and Linezolid

Туберкулез и болезни лёгких, 2023
The objective: assessment of changes in the parameters of complete blood count, clinical urine tests, and blood chemistry during chemotherapy of patients with MDR/XDR pulmonary tuberculosis receiving the short-course regimen containing bedaquiline ...
R. Yu. Abdullaev, A. M. Tikhonov, V. A. Shorokhova, O. G. Komissarova   +3 more
doaj   +1 more source

Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.

PLoS Pathogens, 2020
Our inability to predict which mutations could result in antibiotic resistance has made it difficult to rapidly identify the emergence of resistance, identify pre-existing resistant populations, and manage our use of antibiotics to effectively treat ...
Brendon M Lee, Liam K Harold, Deepak V Almeida, Livnat Afriat-Jurnou, Htin Lin Aung, Brian M Forde, Kiel Hards, Sacha J Pidot, F Hafna Ahmed, A Elaaf Mohamed, Matthew C Taylor, Nicholas P West, Timothy P Stinear, Chris Greening, Scott A Beatson, Eric L Nuermberger, Gregory M Cook, Colin J Jackson   +17 more
doaj   +1 more source

Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases

Molecules, 2020
Nitroimidazole drugs have a long history as therapeutic agents to treat bacterial and parasitic diseases. The discovery in 1989 of a bicyclic nitroimidazole lead, displaying in vitro and in vivo antitubercular activity, spurred intensive exploration of ...
Hollis D. Showalter
doaj   +1 more source

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

Molecules, 2020
Background: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs.
Anas Najjar, Abderrahman Najjar, Rafik Karaman   +2 more
doaj   +1 more source

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date

Drug Design, Development and Therapy, 2021
Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly difficult to treat, and the number of effective agents is dwindling.
Stancil,Stephani L, Mirzayev,Fuad, Abdel-Rahman,Susan M   +2 more
openaire   +4 more sources

High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates

Emerging Microbes and Infections, 2022
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) make TB difficult to control. Global susceptibility data for six newly recommended anti-TB drugs against M/XDR-TB are still limited.
Kanwara Trisakul, Ditthawat Nonghanphithak, Pratchakan Chaiyachat, Orawee Kaewprasert, Kankanon Sakmongkoljit, Wipa Reechaipichitkul, Angkana Chaiprasert, David Blair, Taane G. Clark, Kiatichai Faksri   +9 more
doaj   +1 more source

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

The International Journal of Tuberculosis and Lung Disease, 2021
BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ) or 4 months (4Pa200MZ); 100 mg pretomanid daily for 4 months in the ...
Conor Tweed, Genevieve H. Wills, Angela M. Crook, Evans Amukoye, Vincent M. Balanag, Andrea Yu‐Lin Ban, Anna Bateson, Matthew C Betteridge, William Brumskine, Janice Caoili, Richard E. Chaisson, Müge Çevik, Francesca Conradie, Rodney Dawson, Angelo Del Parigi, Andreas H. Diacon, Daniel E. Everitt, Stella M. Fabiane, Robert D. Hunt, Ahmad Izuanuddin Ismail, Umesh Lalloo, Leandra Lombard, Cheryl Louw, Mookho Malahleha, Timothy D. McHugh, Carl M. Mendel, Francis Mhimbira, Ronelle Moodliar, Videlis Nduba, Andrew Nunn, Issa Sabi, Modulakgotla Sebe, Raesibe Ap Selepe, Suzanne Staples, Susan Swindells, C.H. van Niekerk, Ebrahim Variava, Melvin Spigelman, Stephen H. Gillespie   +38 more
openaire   +5 more sources